A multicenter French study led by Rennes University Hospital reports potential benefits of glucagon-like peptide-1 receptor ...

一种新的肥胖症治疗方法不再以神经元为靶点，而是针对大脑中的支持细胞，从而在不引起恶心的情况下实现减重和更好的血糖控制。人体试验有望在几年内开始。 目前市场上的减肥和糖尿病药物通常无法帮助患者实现长期减重。胰高血糖素样肽-1（Glucagon-like ...

这个“三人小分队”的力量，不仅可以保护“细菌柯南”，还可以为人类所用。想象一下，未来的宇航员在执行深空任务时，可以穿上这种“防护服”，就能免受宇宙辐射的伤害；或者在核事故等紧急情况下，让人们迅速得到保护；甚至在生产疫苗时，这种抗氧化剂也能发挥重要作用。

Glucagon-like peptide 1 receptor agonists, including semaglutide, have increased in use and will continue to increase due to their effectiveness in weight loss.

The metabolism of GLP-1 in the body is extremely rapid and the peptide gets inactivated by the enzyme dipeptidyl peptidase-4 (DPP-4), even before leaving the gut. 3 Glucagon is a key hormone in ...

Serena Williams wants to be transparent and is opening up about her fitness journey, revealing she's taking a GLP-1 ...

Glucagon-like peptide-1 (7–36) amide (GLP-1) is a gut hormone released from the L cells in the mucosa of the jejunum, ileum and colon in response to the ingestion of carbohydrate and fat.

The glucagon-like peptide 1 market size has grown strongly in recent years. It will grow from $20.88 billion in 2024 to $22.37 billion in 2025 at a compound annual growth rate (CAGR) of 7.1%.

Discover a study exploring how GLP-1 receptor agonists may reduce symptoms of hidradenitis suppurativa through weight loss and anti-inflammatory effects.

The global Glucagon-like Peptide 1 (GLP-1) market is set to attain a market value of US$18.75 billion by 2023, driven by a robust Compound Annual Growth Rate (CAGR) of 6.48% during the projected ...